- US-listed companies
- LIPELLA PHARMACEUTICALS INC.
- Income statement
LIPELLA PHARMACEUTICALS INC.【LIPO】Income statement
Market cap
$781.79K
P/E ratio
| 2022/12 | 2023/12 | 2024/12 | |
| Revenue | 184,156 | 449,617 | 536,357 |
| Revenue growth (%) | - | ||
| Research & development | 3 | 3 | 4 |
| Operating margin (%) | |||
| Operating income | -2,589,713 | -4,745,953 | -5,080,542 |
| Income before tax | -2,597,692 | -4,618,965 | -5,016,264 |
| Pretax margin (%) | -1,410.6 | -1,027.3 | -935.2 |
| Net income | -2,597,692 | -4,618,965 | -5,016,264 |
| Net income margin (%) | |||
| Earnings per share | -0.64 | -0.77 | -4.79 |
| Diluted EPS | -0.64 | -0.77 | -4.79 |
| EBITDA | - | ||
| EBITDA margin (%) | - |